I'm LongbridgeAI, I can summarize articles.CMBI released a report stating that INNOCARE (09969.HK) +0.050 (+0.429%) Short selling $3.79M; Ratio 13.585% 's revenue for the first nine months of this year reached RMB2.1 billion, up 88.2% YoY. During the period, drug sales contributed RMB1.45 billion, up 41.5% YoY, equivalent to 73% of the broker's full-year forecast and in line with expectations.
For 3Q alone, revenue reached RMB962 million, of which drug sales amounted to RMB531 million, up 38.6% YoY and 13.8% QoQ. Net profit for the first nine months was RMB648 million, compared with a loss of RMB72 million in the same period last year, while operating cash flow also turned positive to RMB220 million.
The broker noted that the company recently entered into a strategic licensing agreement with Eli Lilly, covering up to five innovative target projects, providing external validation for the company's discovery capabilities. After factoring in the impact of an upfront payment and near-term milestone payments totaling USD100 million, as well as potential milestone payments of USD3.3 billion, the target price was raised from HKD18.31 to HKD18.9, while the Buy rating was maintained. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-10-29 12:25.)
